Summary: Psychiatric Times details the presentations of top researchers at the American Psychiatric Association (APA) Annual Meeting this year, highlighting the results of clinical trials involving MDMA-assisted therapy. In the first MAPS-sponsored Phase 3 clinical trial that investigated the combination of MDMA and therapy in the treatment of PTSD, “67% of participants no longer met criteria for PTSD after 2 months of treatment with MDMA combined with therapy.”
Originally appearing here.
